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Abstract
Background Since head and neck cancer is characterized by
poor survival rates, there is a demand for novel therapeutic
targets and prognostic biomarkers. An upcoming therapeutic
target is the fibroblast growth factor receptor (FGFR) family.
However, their prognostic role in head and neck cancer re-
mains unclear.
Objective To systematically review current evidence on
the prognostic value of FGFR family members in head
and neck squamous cell carcinoma (HNSCC).
Methods A systematic search of PubMed, Embase, and the
Cochrane Library was performed for publications up to 14
May 2014. Two reviewers screened all articles and included
prognostic studies on the molecular biomarkers FGFR1-5 in
any type of HNSCC. Relevant studies were assessed on risk of
bias using the Quality in Prognostic Studies (QUIPS) tool.
Data on FGFR aberrations and survival outcome were extract-
ed from relevant studies. The prognostic value of FGFR ab-
errations was compared among studies.
Results The initial search yielded 1568 publications of which
12 fulfilled the inclusion criteria. Four studies reported
FGFR1 gene amplification (9.3–17.4 %) and FGFR1 protein
overexpression (11.8 %) in HNSCC. FGFR1 protein expres-
sion by cancer-associated fibroblasts correlated with poor
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survival outcome in one study (p<0.01). Eight studies report-
ed high rates of FGFR4 Gly388Arg polymorphisms (32.5–
54.2 %) and FGFR4 protein overexpression (16–35 %), with
varying correlations with survival. So far, no studies assessed
the prognostic role of FGFR2, FGFR3, or FGFR5 in HNSCC.
Limitations Significant risk of bias has been identified among
included studies. Therefore, cautious interpretation of the re-
sults is recommended.
Conclusion In conclusion, evidence was found for prognos-
tic value of FGFR1 expression in cancer-associated fibro-
blasts in HNSCC. Prognostic evidence on the other FGFR
family members in HNSCC is limited and conflicting. This
emphasizes the need for future well-conducted prognostic
studies.
1 Introduction
With 350,000 deaths each year, head and neck cancer ac-
counts for a significant part of global cancer mortality and is
the sixth most common cancer worldwide, affectingmore than
650,000 people each year [1]. The most common types of
head and neck cancer are laryngeal, oral, and oropharyngeal
cancer [2]. Although more than 95 % of these cancers are
squamous cell carcinoma, clinical and molecular characteris-
tics of these tumors are heterogeneous [3–5]. Frequently, head
and neck squamous cell carcinoma (HNSCC) is detected at an
advanced stage implying that the primary tumor has already
metastasized to the neck. Advanced stage HNSCC is nowa-
days treated with varying combinations of radiation therapy,
chemotherapy and surgery.
Current chemoradiation therapy regimens cause severe
short- and long-term side-effects in more than 80 % of
HNSCC patients [6]. Additionally, 5-year relative survival
rates have slightly improved over the past three decades, but
remain low at 65 %. Persisting poor survival rates of HNSCC
with current treatment regimens have led to a search for novel
therapeutic targets and prognostic biomarkers [6, 7]. The ef-
fort to resolve these problems has led to a quest for novel
predictive and prognostic biomarkers with the intention to
individualize treatment and reserve aggressive therapy for bi-
ologically aggressive tumors. As a result, molecular carcino-
genesis has become a major focus of cancer research. Previous
research endeavors in the pursuit of novel therapeutic targets
have identified potential predictive and prognostic molecular
biomarkers in HNSCC [3, 8]. One of them is the fibroblast
growth factor receptor (FGFR) family [9].
FGFRs are upcoming promising therapeutic targets and
possible prognostic biomarkers in multiple types of cancer,
including HNSCC [9, 10]. The FGFR family comprises five
(FGFR1–5) cell membrane-bound tyrosine kinase receptors
linked to multiple intracellular downstream signaling path-
ways. FGFRs regulate tissue homeostasis in normal human
tissues [11, 12]. In cancer cells, oncogenic aberrations in
FGFR pathway-related genes dysregulate and constitutively
activate the FGFR pathway, resulting in particular hallmark
capabilities in cancer cells: to sustain proliferative signaling,
resist cell death, induce angiogenesis, and activate invasion by
cell migration [13–15]. These genomic aberrations include
gene fusion, translocation, amplification, and somatic DNA
mutations [9]. Because of their major role in cancer cell biol-
ogy, FGFR family members provide promising opportunities
for targeted therapies in a wide spectrum of solid tumors [9,
16, 17]. In addition, previous studies have identified a possible
role of FGFRs as prognostic biomarkers, by which they could
select patients for adjuvant systemic therapy [18, 19].
However, the prognostic value of FGFRs in HNSCC remains
a subject of debate and has not yet been reviewed in this type
of cancer. Therefore, the aim of this s tudy was
to systematically review current evidence on the prognostic
value of FGFR1–5 in HNSCC and analyze it in a clinically
relevant meta-analysis.
2 Materials and Methods
2.1 Eligibility Criteria and Information Sources
Studies were eligible for inclusion if they were English orig-
inal articles and addressed the prognostic value of FGFRs in
any type of HNSCC (i.e. overall survival, disease-specific
survival, disease-free survival, recurrence-free survival, or
progression-free survival). FGFR was required to be investi-
gated as a molecular biomarker with laboratory techniques
(protein expression, gene amplification, mutation, translation,
polymorphism, or mRNA). Original articles were defined as
primary research studies with new, unpublished results and
written by the researchers who performed the study. Studies
were excluded if they investigated fibroblast growth factor
(FGF) instead of FGFR, had no prognostic study design, were
repetitive studies on same samples, or were non-English.
Also, animal studies, case reports, reviews, meta-analysis,
and commentaries were excluded. A systematic search of
PubMed, Embase, and the Cochrane Library was performed
for publications up to 14 May 2014.
2.2 Search Strategy and Study Selection
The search terms ‘FGFR1–5’ and ‘head and neck cancer’with
all relevant synonyms were used (Online resource 1). Using
predefined inclusion and exclusion criteria, two authors (NI
and KL) independently screened all retrieved records on title
and abstract and excluded duplicate titles to select potentially
eligible articles. Subsequently, relevant articles were screened
on full text, and a further selection of eligible articles was
made on relevance of full text. Finally, review articles on this
18 N. A. Ipenburg et al.
topic and references of selected articles were manually
screened for titles not identified by the initial search.
Selection was based on consensus.
2.3 Data Collection and Data Items
Two authors independently (NI and KL) extracted all data of
the selected studies using a standardized data extraction form.
Discrepancies were resolved by discussion. The following
information was extracted from each study: first author’s
name, year of publication, sample size, head and neck site,
treatment, FGFR aberration investigated, type of survival out-
come, patient material, laboratory techniques, statistical anal-
ysis, cut-off value (if applicable), prevalence of FGFR aberra-
tion, correlations with survival outcome, and length of follow-
up.
2.4 Risk of Bias in Individual Studies
The methodological quality of the remaining eligible articles
was independently assessed by two reviewers (NI and KL),
using criteria of the Quality In Prognosis Studies (QUIPS) tool
[20]. This tool has been evaluated in 43 groups reviewing
prognostic studies and has been identified as a reliable and
useful tool for systematic reviewers. Among nine review
groups, inter-rater agreement statistic (kappa) varied between
0.56–0.82 [21]. According to the QUIPS tool, risk of bias was
scored as low, moderate or high for the following six items;
study participation, study attrition, prognostic factor measure-
ment, outcome measurement, study confounding and statisti-
cal analysis, and reporting (Online resource 2). Studies scor-
ing low risk of bias on three or more items were considered to
be of ‘high’ methodological quality, while studies scoring
high risk of bias on three or more items were considered to
be of ‘low’ methodological quality. All other studies were of
moderate quality. The use of proper positive and negative
controls for laboratory techniques on FGFR and the use of
well-defined scoring criteria for FGFR aberrations were also
considered as methodological quality criteria. When there was
disagreement on (certain items of) risk of bias of a study, two
authors (NI and KL) discussed reasons for disagreement in
order to mutually agree on final risk of bias score using the
QUIPS tool (Online resource 2).
2.5 Synthesis of Results
Because of clinical and methodological heterogeneity of the
included studies (study population, type of survival outcome,
material, techniques, cut-off values, and applied statistical
models), results were not quantitatively pooled. Therefore, a
clinically relevant meta-analysis could not be performed. A
forest plot was produced using Comprehensive Meta-
Analysis Version 2.2.064 software (Biostat, Englewood, NJ,
USA).
3 Results
3.1 Search and Selection
The initial search yielded 1568 unique articles (Fig. 1). One
Chinese article could not be screened because no abstract or
full text was available [22]. Therefore, 41 English language,
full-text articles were evaluated in more detail, of which 12
original articles met our inclusion criteria. Cross-reference
checking revealed no additional relevant publications. Of the-
se 12 included articles, four determined the prognostic value
of FGFR1 in HNSCC and eight determined the prognostic
value of FGFR4 by laboratory techniques. Of all 12 studies,
Choi et al. had the smallest study population of 24 patients
[23]. Seven studies had a study population of mixed HNSCC
types, and five studies had a study population of only one type
of HNSCC. None of the studies included other types of cancer
than HNSCC. In all studies patients were followed in time, but
two did not specify the type of survival outcome measured nor
the duration of follow-up. All studies accept one analyzed
survival outcome using statistical methods such as Log-rank
test or Cox proportional hazards model. Furthermore, repeti-
tive studies on similar samples were not found. No articles
assessed the prognostic value of FGFR2 or FGFR3 in
HNSCC.
3.2 Quality Assessment
According to the QUIPS tool, the quality of included studies
ranged from high to low. This was mainly because blinding of
observers was absent, outcomes were not standardized, and
Cox proportional hazard models to control for confounding
factors were not performed (Table 1). Three studies did not
use proper positive and negative controls for the laboratory
techniques [19, 25, 27]. All studies used well-defined criteria
for scoring FGFR aberrations. Two studies were of high qual-
ity [18, 29], four of moderate quality [19, 23, 25, 30], and six
studies were of low quality [24, 26–28, 31, 32]. No studies
were excluded based on methodological quality.
3.3 FGFR1 Gene Amplification and FGFR1 Protein
Overexpression as Prognostic Biomarkers
Altogether, four studies on FGFR1 included a total of 993
patients with sample sizes ranging from 61 to 555 samples.
Three of them determined FGFR1 gene copy number status
and two FGFR1 protein expression (Table 2) [24–27]. Similar
fluorescence in situ hybridization (FISH) and immunohisto-
chemical (IHC) techniques were used to determine FGFR1
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Fig. 1 Flowchart of study selection process (date of search: 14th ofMay, 2014). FGFR1–5, fibroblast growth factor receptor 1–5; FGF, fibroblast growth
factor; HNSCC, head and neck squamous cell carcinoma















FGFR1 Göke (2013) [24] ◖ ● ◖ ● ● ●
Young (2013) [25] ◖ ◖ ◖ ○ ● ●
Freier (2007) [26] ● ◖ ◖ ● ● ●
Hase (2006) [27] ◖ ◖ ◖ ● ● ●
FGFR4 Farnebo (2013) [28] ◖ ◖ ○ ● ● ●
Dutra (2012) [18] ○ ○ ◖ ○ ◖ ◖
Choi (2012) [23] ◖ ◖ ○ ○ ● ●
Azad (2012) [29] ◖ ○ ○ ○ ○ ◖
Tanuma (2010) [30] ◖ ◖ ○ ● ◖ ◖
Ansell (2009) [31] ◖ ◖ ○ ● ● ●
Da Costa Andrade
(2007) [19]
◖ ◖ ○ ● ◖ ◖
Streit (2004) [32] ◖ ◖ ◖ ● ● ●
Risk of bias: ○ = low risk; ◖ = moderate risk; ●high risk
FGFR, fibroblast growth factor receptor; FGFR1, fibroblast growth factor receptor 1; FGFR4, fibroblast growth factor receptor 4
a The included studies were assessed on items of methodological quality using the QUIPS assessment tool. An elaborate description of each QUIPS item
is provided by Hayden et al. [20] and in Online source 2
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copy number changes and FGFR1 protein expression. Cut-off
values for FGFR1 protein overexpression as well as FGFR1
gene amplification varied among these studies (Table 3). In
addition, different outcomemeasures, such as overall survival,
progression-free survival, recurrence-free survival, and sur-
vival outcome not specified, were used in these studies.
None used multivariable Cox proportional hazard models to
control for confounding factors.
A high prevalence of FGFR1 gene amplification (9.3–
17.4 %) was found in HNSCC, and a high prevalence
FGFR1 protein overexpression was found in oral SCC
(11.8 %; Table 3) [24–27]. FGFR1 gene amplification and
FGFR1 protein expression in HNSCC were not significantly
correlated to any measure of survival [24–26]. Overall surviv-
al and progression-free survival hazard ratios for FGFR1 am-
plification versus normal copy number pointed in the same
direction (overall survival: HR=0.94; 95 % CI=0.37–2.39;
progression-free survival: HR=0.79; 95 % CI=0.24–2.58;
Fig. 2) [25]. However, one study found a significantly worse
survival for FGFR1 protein expression in cancer-associated
fibroblasts (p<0.01) [27].
3.4 FGFR4 Gly388Arg Polymorphism and FGFR4
Protein Overexpression as Prognostic Biomarkers
Eight studies investigated the relationship between FGFR4
Gly388Arg polymorphism and survival in HNSCC; two of
them also determined FGFR4 protein expression in relation
to survival (Table 2) [18, 19, 23, 28–32]. In total, these studies
included 1159 patients with sample sizes ranging from 24 to
531. Study population, head and neck regions, materials and
techniques, cut-off values to define protein overexpression,
survival outcome measures, and length of follow-up varied
considerably among all studies. Regarding statistical analysis,
only four studies used a Cox proportional hazards model to
control for confounding factors.
Overall, a high prevalence of the FGFR4 Gly388Arg poly-
morphism (32.5-54.2 %) was found in HNSCC (Table 3). The
Arg/Arg genotype occurred in fewer HNSCC cases (5–
15.3%), whereas wild type (Gly/Gly) occurredmore frequent-
ly (37.5–67.5 %). Comparing overall survival outcome for the
FGFR4 Gly388Arg polymorphism, studies reported longer,
equivalent, and even shorter survival rates [19, 23, 28–31].
One study found worse disease-specific survival while anoth-
er study found no relationship with survival [18, 23].
Regarding disease-free survival, two studies reported no sig-
nificant correlation with the FGFR4 Gly388Arg polymor-
phism [18, 29]. Overall survival and progression-free survival
hazard ratios for the FGFR4Arg388 allele pointed in opposite
directions among different studies (Fig. 2). Because of non-
symmetric lower and upper limit log values, findings on the
FGFR4 polymorphism found by Tanuma et al. could not be
illustrated in the forest plot [30]. FGFR4 protein
overexpression was related to worse overall survival in
one study and to worse disease-free survival and disease-
specific survival in another study [18, 32]. Other studies
did not investigate the relation of FGFR4 protein expres-
sion to survival.
4 Discussion
During the past decade, multiple molecular biomarkers
which play a role in tumor growth and metastatic spread
have been identified. Molecular carcinogenesis has be-
come a major field of cancer research and is driven by
the need for novel targetable and prognostic molecular
biomarkers. Among these are the FGFR family members
[9]. There is increasing evidence for the therapeutic role
of FGFRs in HNSCC, but their prognostic role
remained unclear.
Herein, we present the first systematic review of cur-
rently available evidence on the prognostic value of
FGFRs in HNSCC. All included articles were critically
appraised using the QUIPS tool items [20]. Studies ad-
dressed the prognostic value of FGFR1 gene amplification,
FGFR1 protein expression, FGFR4 genotype, and FGFR4
protein expression in 1870 HNSCC cases of various sites,
including oral, oropharyngeal, hypopharyngeal, and laryn-
geal SCC. To date, 12 studies focused on the prognostic
value of FGFRs in HNSCC [18, 19, 23–32]. While our
extensive search retrieved multiple articles reporting on
FGFR2 and FGFR3 in HNSCC, none of these studies
assessed their prognostic value [33–39]. Therefore, only
FGFR1 and FGFR4 could be assessed as prognostic bio-
markers in HNSCC.
Current evidence suggests that FGFR1 gene amplifica-
tion and protein overexpression are not prognostic bio-
markers of value in HNSCC. However, in one study,
FGFR1 protein expression in cancer-associated fibroblasts
of HNSCC was a prognostic biomarker which should be
validated in a larger cohort [27]. Interestingly, evidence on
the prognostic value of the FGFR4 Gly388Arg polymor-
phism was conflicting [18, 19, 23, 28–32]. This could
possibly be explained by differences in duration of
follow-up time among studies with positive and negative
results. In one study, differences in overall survival only
occurred after 24 months of follow-up, while two out of
three studies with negative results had a follow-up period
of less than three years [23, 31, 32]. This in contrast to
positive results in the other four studies with a follow-up
time of more than 3 years [18, 19, 28, 30]. Remarkably,
studies with statistically significant survival results used
FFPE tissues, while studies without significant results
used DNA from either fresh frozen tumor tissue, periph-
eral blood, or cell lines [18, 19, 23, 28–32]. Perhaps the
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type of study material may influence the PCR techniques
used to detect the FGFR4 Gly388Arg polymorphism.
Differences in tumor localization of HNSCC might ex-
plain the conflicting results on DFS related to the
FGFR4 Gly388Arg polymorphism found by Azad et al
and Dutra et al [18, 29]. Azad et al also included
hypopharyngeal and laryngeal tumors besides oral and
oropharyngeal tumors. HNSCC from different anatomical
locations show different clinical and molecular character-
istics and are acknowledged as different entities. As such,
tumor localization might affect patient outcome. Other
differences in study populations or patient treatment could
not explain the conflicting results. However, none of the
studies were non-randomized controlled trials.
The prognostic value of FGFR has been investigated in
numerous other types of cancer. Our findings are in agree-
ment with studies on other types of cancer that also
showed conflicting results. For example, studies on
FGFR1 gene amplification and FGFR4 Gly388Arg poly-
morphism in lung SCC [40–46] and breast cancer [47–49]
reported conflicting results on overall survival and
disease-free survival. Only studies on FGFR3 mutations
in bladder cancer are in agreement with each other; nearly
all studies found correlations with better progression-free
survival and disease-specific survival [50]. For all other
FGFRs in cancer, evidence on their prognostic value is
limited or absent and therefore inconclusive, which is
similar to HNSCC.
This review focusses on the prognostic value of FGFR
aberrations in HNSCC. These prognostic associations do
not necessarily predict the response to FGFR-inhibitor
therapy as the latter is mainly, yet exclusively, predicted
by the underlying aberration itself. For example, previous
clinical studies in breast and lung cancer showed that
FGFR-inhibitor therapies were only effective in FGFR-
amplified or FGFR-mutated tumors [51, 52]. The FGFR
genes are frequently aberrated in HNSCC, FGFR1 is
amplified in 10 % of HPV-negative HNSCC and
FGFR3 is aberrated in 11 % of HPV-positive HNSCC
[53]. As such, HNSCC patients with FGFR-aberrated
tumors may benefit from FGFR-inhibitor therapies as
these tumors may be sensitive. In addition, targeting
FGFR family members has shown to enhance radiother-
apy and chemotherapy sensitivity of cancer cells.
Radiotherapy resistant cancer cells upregulate FGFR3
protein and chemoradiotherapy resistant cancer cells up-
regulate FGFR4 protein. Targeting FGFR3 in resistant
HNSCC cells restored sensitivity to radiotherapy and
targeting FGFR4 restored sensitivity to chemoradiothera-
py [54–56].
The probative value of the present review depends on
methodological quality of included studies to some extent.
All included studies have their specific strengths but the meth-
odological quality is questionable inmany. Poor description of
study populations and incomplete data in two studies might
have introduced selection bias [24, 25]. Six studies had a
mean/median follow-up time less than three years [23, 24,
26–28, 31]. Risk of information bias is present in all in-
cluded studies as none of them provided information on
blinding of investigators for the current vital status of
patients. Survival rate was only standardized in one study
[25]. In all other studies, the definition and assessment of
the specific survival outcomes were unclear. Some articles
have relatively low sample sizes and did not use multivar-
iable statistical methods, such as multivariable Cox propor-
tional hazard models. Because of risk of bias among in-
cluded studies, cautious interpretation of results is
recommended.
5 Conclusion
In conclusion, high quality evidence regarding the prognostic
role of FGFR in HNSCC patients is largely lacking. Current
Fig. 2 Forest plot of HNSCC survival grouped by FGFR family member
and comparison. AMP, amplification; Arg388, FGFR4 Arg388 allele; CI,
confidence interval; DFS, disease-free survival; DSS, disease-specific
survival; FGFR, fibroblast growth factor receptor; HR, hazard ratio;
NCN, normal copy number; NOS, not otherwise specified; OS, overall
survival; PE, protein expression; PFS, progression-free survival; RP, risk
profile; WT, wild type. Hazard ratios are illustrated as squared boxes and
corresponding 95 % confidence intervals are illustrated as error bars
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evidence on FGFR1 in HNSCC is limited to only very few
studies. This limited evidence suggests that FGFR1 gene am-
plification and FGFR1 protein expression are not of value as
prognostic biomarkers in HNSCC. However, FGFR1 protein
expression in HNSCC-related fibroblasts holds promising
prognostic value, but evidence is too limited to draw conclu-
sions yet. The evidence on FGFR4 Gly388Arg polymor-
phisms in HNSCC is conflicting and inconclusive. FGFR4
protein overexpression may serve as a prognostic biomarker,
but evidence is also too limited to draw conclusions yet.
Future research should determine the prognostic value of
FGFR1-5 in HNSCC and clarify conflicting results
concerning the FGFR4 Gly388Arg polymorphism in HNSC
C.
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